Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease
Abstract Background Retrospective observational studies may provide real-world evidence about long-acting muscarinic receptor antagonist (LAMA) effectiveness in reducing mortality or COPD-related readmission risk after a COPD hospitalization. Causal inference and competing risk statistical procedure...
Saved in:
Main Authors: | Melissa H. Roberts (Author), Douglas W. Mapel (Author), Hans Petersen (Author) |
---|---|
Format: | Book |
Published: |
Adis, Springer Healthcare,
2019-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
by: Ora J, et al.
Published: (2020) -
Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol
by: Matera MG, et al.
Published: (2015) -
Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease
by: Burkes RM, et al.
Published: (2020) -
Critical reappraisal of short-acting bronchodilators for pediatric respiratory diseases
by: Amelia Licari, et al.
Published: (2024) -
Pharmacokinetics, metabolite profiling, safety, and tolerability of inhalation aerosol of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, in healthy Chinese subjects
by: Huaye Gao, et al.
Published: (2022)